TY - JOUR
T1 - Therapeutic effect of bilastine in Japanese cedar pollinosis using an artificial exposure chamber (OHIO Chamber)
AU - Hashiguchi, Kazuhiro
AU - Wakabayashi, Ken ichiro
AU - Togawa, Michinori
AU - Saito, Akihiro
AU - Okubo, Kimihiro
N1 - Funding Information:
The authors gratefully acknowledge Drs. Lourdes Azc?rate, Rom?n Valiente, and Luis Labeaga (Faes Farma S.A., Spain) for their scientific review of the manuscript. The authors would also like to thank Satoko Shimizu and all the members who participated in this study at the Tokyo Research Center of Clinical Pharmacology for the construction of the OHIO Chamber as well as managing and coordinating the tests and subject's visiting schedule. We would also like to thank Keika Tsuruya and Yusuke Iida (Taiho Pharmaceutical) who played an overall management role in the study. This study was funded by Taiho Pharmaceutical, Tokyo, Japan.
Publisher Copyright:
© 2016 Japanese Society of Allergology
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Background Environmental exposure chambers have been used to expose subjects to aeroallergens to investigate the efficacy of prophylactic treatment with symptomatic agents in Japan. We first examined the therapeutic effect of bilastine (BIL), a novel non-sedative second-generation H1-antihistamine, in subjects with Japanese cedar pollinosis using an artificial exposure chamber (OHIO Chamber). Methods This was a randomized, double-blind, four-way crossover, placebo- and active-controlled phase II study (trial registration number JapicCTI-132213). Subjects were exposed to cedar pollen (8000 grains/m3) for 2 h on Day −1 and 4 h each on Day 1 and 2. BIL 10 or 20 mg, placebo, or fexofenadine hydrochloride (FEX) 60 mg was administered orally 1 h after the start of pollen exposure on Day 1. Placebo or FEX was administered 12 h after the first dosing. The primary efficacy endpoint was the sum of total nasal symptom score (TNSS) from 0 to 3 h after the Day 1 dosing. Results We enrolled 136 subjects and the sum of TNSS on Day 1 of the three active treatments was significantly lower than that of placebo and was maintained up to 26 h after the first dosing (Day 2). The sum of TNSS or sneezing score on Day 1 after BIL 20 mg was more significantly decreased than after FEX. Moreover, BIL showed a faster onset of action than FEX. Conclusions We demonstrated the efficacy, rapid onset, and long duration of action of BIL in subjects with Japanese cedar pollinosis exposed to cedar pollen using the OHIO Chamber.
AB - Background Environmental exposure chambers have been used to expose subjects to aeroallergens to investigate the efficacy of prophylactic treatment with symptomatic agents in Japan. We first examined the therapeutic effect of bilastine (BIL), a novel non-sedative second-generation H1-antihistamine, in subjects with Japanese cedar pollinosis using an artificial exposure chamber (OHIO Chamber). Methods This was a randomized, double-blind, four-way crossover, placebo- and active-controlled phase II study (trial registration number JapicCTI-132213). Subjects were exposed to cedar pollen (8000 grains/m3) for 2 h on Day −1 and 4 h each on Day 1 and 2. BIL 10 or 20 mg, placebo, or fexofenadine hydrochloride (FEX) 60 mg was administered orally 1 h after the start of pollen exposure on Day 1. Placebo or FEX was administered 12 h after the first dosing. The primary efficacy endpoint was the sum of total nasal symptom score (TNSS) from 0 to 3 h after the Day 1 dosing. Results We enrolled 136 subjects and the sum of TNSS on Day 1 of the three active treatments was significantly lower than that of placebo and was maintained up to 26 h after the first dosing (Day 2). The sum of TNSS or sneezing score on Day 1 after BIL 20 mg was more significantly decreased than after FEX. Moreover, BIL showed a faster onset of action than FEX. Conclusions We demonstrated the efficacy, rapid onset, and long duration of action of BIL in subjects with Japanese cedar pollinosis exposed to cedar pollen using the OHIO Chamber.
KW - Bilastine
KW - Fexofenadine
KW - H-antihistamine
KW - OHIO Chamber
KW - Therapeutic effect
UR - http://www.scopus.com/inward/record.url?scp=84997142607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84997142607&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2016.06.009
DO - 10.1016/j.alit.2016.06.009
M3 - Article
C2 - 27475625
AN - SCOPUS:84997142607
VL - 66
SP - 123
EP - 131
JO - Allergology International
JF - Allergology International
SN - 1323-8930
IS - 1
ER -